Compass pathways stock forecast.

Nov 13, 2021 · A buy now? Luckily, Compass Pathways stock doesn't have a rousing success for COMP360 already baked into its price. The company's market cap of $1.4 billion at the moment isn't terribly high for a ... Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...WebCompass Pathways Plc. Market Cap. $399M. Today's Change. (6.61%) $0.40. Current Price. $6.45. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may ...Upgrade Your Account ... COMPASS Pathways plc NASDAQ: CMPS is a United Kingdom-based mental healthcare company developing psilocybin therapy through late-stage ...

Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 38.00, with a high estimate of 120.00 and a low estimate of 22.00. The median estimate represents a +488.24% increase from the last price of 6.46.

Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. ... Analyst Forecast. The ...Summary. BiotechValley Insights is initiating coverage of COMPASS Pathways with a "Bearish" rating at a $13 PT. CMPS has filed an IPO with an initial valuation of US$544M; since then, the stock ...

The average Atai Life Sciences Nv stock price prediction forecasts a potential upside of 1,490.91% from the current ATAI share price of $1.10. What is ATAI's forecast return on equity (ROE) for 2023-2026? (NASDAQ: ATAI) forecast ROE …What is the current Price Target and Forecast for COMPASS Pathways (CMPS) COMPASS Pathways (CMPS) (Real Time Quote from BATS) $5.93 USD +0.10 …The financials. The average price target from the nine analysts following COMPASS pathways is $68 against a current price of $14.9, implying a 356% upside and a target market cap of $3 billion. I ...Key Points. Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices. Wall Street analysts have ...

These psychedelic sector stocks are generating a buzz among investors. ... Compass Pathways PLC -26.3%: Incannex Healthcare Ltd. -69.6% ... Commercial Real Estate Outlook for 2024.

According to COMPASS Pathways's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.54468. At the end of 2022 ...

A. While ratings are subjective and will change, the latest Compass Pathways ( CMPS) rating was a reiterated with a price target of $0.00 to $21.00. The current price Compass Pathways ( CMPS) is ...What happened. Shares of the mental healthcare company Compass Pathways ( CMPS 1.87%) rose by a noteworthy 15.8% through the first four days of trading this week, according to data from S&P Global ...Nov 29, 2023 · View COMPASS Pathways PLC Sponsored ADR CMPS investment & stock information. Get the latest COMPASS Pathways PLC Sponsored ADR CMPS detailed stock quotes, stock data, Real-Time ECN, charts, stats ... Nov 29, 2022 · That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51% ... 13 de mar. de 2023 ... Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their 'Buy' rating and US$60 price target for COMPASS Pathways after the ...

The consensus 12-month price target for Compass Pathways reflects an upside potential of close to 325%. Even the most pessimistic analyst surveyed by Refinitiv thinks that the stock will double ...The latest price target for Compass Pathways ( NASDAQ: CMPS) was reported by Cantor Fitzgerald on Tuesday, August 22, 2023. The analyst firm set a price target for 21.00 expecting CMPS to rise to ...WebDec 1, 2023 · CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings results on November 2nd, 2023. The reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted earnings per share). Compass Pathways (CMPS) buy sell technical analysis & forecast predictions with share price targets for today short term. Compass Pathways (CMPS) Share trades in NASDAQ in NASDAQ stock exchange. Important intraday levels for the stock on upside are: 10 and 11 and 12 If the stock moves up, then it will find resistance near these levels.COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).The financials. The average price target from the nine analysts following COMPASS pathways is $68 against a current price of $14.9, implying a 356% upside and a target market cap of $3 billion. I ...16 de ago. de 2023 ... ... Price” requirement (as defined in the Nasdaq rules). COMPASS intends to use the net proceeds from the proposed financing to fund its pivotal ...

Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ... Shares of Compass Pathways (CMPS 6.61%) have soared since the company's recent stock market debut as support grows for the use of popular recreational drugs to combat depression.

Compass, Inc. (NYSE:COMP) announced its quarterly earnings data on Monday, November, 6th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.35 billion.WebUS20451W1018. Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and …Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...COMPASS Pathways - Overview (February Company Presentation) Recent Events: Compass posted fourth quarter results one week ago. The company posted a net loss of $25.7 million for the quarter and ...See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Compass Pathways to participate in upcoming Evercore investor conference. LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat …

COMPASS Pathways PLC (CMPS) stock is down -1.77% while the S&P 500 is higher by 1.89% as of 2:59 PM on Thursday, Apr 27. CMPS has fallen -$0.15 from the previous closing price of $8.17 on volume of 236,713 shares. Over the past year the S&P 500 has fallen -1.22% while CMPS has fallen -21.27%. CMPS lost -$0.01 per share the …

Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years.

First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 . Compass Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in …... Stock Price Chart Interactive Chart > · Price chart for CMPS. COMPASS Pathways PLC ADR (CMPS) Company Bio. COMPASS Pathways plc operates as a mental health care ...Compass IPO'd in September 2020, raising $147m at $17 per share, so the stock is only trading at a 35%-40% discount to its listing price, which is not too bad based on current biotech bear market ...COMPASS PATHWAYS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie COMPASS Pathways PLC (spons. ADRs) | A2QCDR | CMPS | US20451W1018 The current Compass Pathways PLC [ CMPS] share price is $6.45. The Score for CMPS is 52, which is 4% above its historic median score of 50, and infers lower risk than normal. CMPS is currently trading in the 50-60% percentile range relative to its …WebStock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Compass Pathways Plc ADR (CMPS) shares have gone down -22.59% during the last six months, with a year-to-date growth rate less than the industry average at -3.70% against 5.90. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 64.40% this quarter and then jump 7.00% in the …WebCOMPASS Pathways plc (CMPS) share price prediction for 2023, 2024, 2025, 2026 and 2027. CMPS one year forecast. Compass Pathways Plc stock monthly and weekly forecasts.WebCOMPASS Pathways ’s (CMPS) stock price is $6.1 and COMPASS Pathways ’s (CMPS) 100-day simple moving average is 7.59, creating a Sell signal. COMPASS Pathways ’s ( CMPS ) stock price is $6.1 and COMPASS Pathways ’s ( CMPS ) 200-day simple moving average is 8.13 , creating a Sell signal. Financial highlights. Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share (including non-cash share-based compensation expense of $4.1 million), compared with $21.2 million or $0.50 loss per share, during the same period in 2022 (including non-cash-share-based compensation expense of $3.1 million).Web

COMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range $5.27 $7.96 52-Week Range $5.01 $11.48 Volume 900,582 shs Average Volume 342,967 shs Market Capitalization $370.16 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ... COMPASS Pathways is looking at the long-term effects of COMP360 in our phase 3 programme in treatment-resistant depression.” Manish Agrawal, MD, Chief Executive Officer, Sunstone Therapies, and the trial’s Principal Investigator, said: “This pioneering study is the first of its kind, conducted within a community hospital cancer center.Instagram:https://instagram. arm stock symbolishares aoastock mgmclipper logistics (Note: COMPASS stock price on Nasdaq jumped between June 30 and July 5, going from $8.10 to currently trading at $8.80 following highest at $9.02 also today, July 5 shortly after opening and ...-1.40 Crude Oil (-0.32%) Gold COMPASS Pathways plc (CMPS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 5.93 -0.05 (-0.84%) At close: 04:00PM EST 6.03 +0.10 (+1.69%) After... best commission free brokersblackrock stock dividend In September of 2020, at $17 per share, Compass Pathways stock completed its public offering. Since the initial offering, CMPS has traded as high as $60 per share and seems to average out in the ... nyse pstg Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ... The average Compass stock price prediction forecasts a potential upside of 35.39% from the current COMP share price of $2.43. What is COMP's forecast return on equity (ROE) for 2023-2026? ( NYSE : COMP ) forecast ROE is N/A , which is considered weak .